Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients | Zendy

Pingzhou Yang | Zendy; Milind Javle | Zendy; Fei Pang | Zendy; Zhao Wei | Zendy; Reham AbdelWahab | Zendy; Xiaofeng Chen | Zendy; Funda MericBernstam | Zendy; Huanwei Chen | Zendy; Mitesh J. Borad | Zendy; Yu Liu | Zendy; Chuntao Zou | Zendy; Shuo Mu | Zendy; Yutong Xing | Zendy; Kai Wang | Zendy; Chuang Peng | Zendy; Xu Che | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients

Author(s) -

Pingzhou Yang,

Milind Javle,

Fei Pang,

Zhao Wei,

Reham AbdelWahab,

Xiaofeng Chen,

Funda MericBernstam,

Huanwei Chen,

Mitesh J. Borad,

Yu Liu,

Chuntao Zou,

Shuo Mu,

Yutong Xing,

Kai Wang,

Chuang Peng,

Xu Che

Publication year - 2019

Publication title -

hepatobiliary surgery and nutrition

Language(s) - English

Resource type - Journals

eISSN - 2304-389X

pISSN - 2304-3881

DOI - 10.21037/hbsn.2019.04.11

Subject(s) - cdkn2a , medicine , gemcitabine , cohort , oncology , gallbladder cancer , cancer , arid1a , mutation , gene , genetics , biology

Gallbladder cancer (GBC) is often diagnosed at an advanced stage with limited therapeutic options and poor prognosis. The five-year survival rate of this cancer when diagnosed at an advanced stage is below 5%, and the median survival time is less than a year with standard gemcitabine-based chemotherapy. Survival benefit with second-line treatment is unknown. Thus, there is an urgent need for novel treatment strategies and targeted therapy based on next generation sequencing (NGS) may be of value.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research